Full Version of the May 2013 Issue
Full version of the May 2013 Targeted Therapy News
Targeted Therapy Newscovers the most important developments in cancer care today, personalized medicine and targeted therapies. The publication is strongly committed to providing oncology healthcare professionals the information and resources they need to deliver the best possible treatment to their patients
This issue features articles on:
- Key targeted trials being presented at ASCO
- Nongenetic mechanisms of cancer cell diversity and treatment response
- Platinum resistance in ovarian cancer
- HER2-targeted agents in NSCLC
Articles in this issue
Bundled Payment: Practice Savior or Killer?
Case-Based Discussion: Integrating Novel Agents Into the Treatment of Prostate Cancer
Notch Holds Promise, but Presents Obstacles as Cancer Target
Trials Examine Use of T-DM1 as Combination Therapy for HER2 Breast Cancer
Spotlight on Novel Agents in Early Development
Treating Elderly Patients With CLL
Biomarkers Still Needed in Prostate Cancer
New Developments in Oral Targeted Agents for Advanced Colorectal Cancer
Researchers Identify How Nongenetic Mechanisms of Cancer Cell Diversity Can Affect Treatment Response
Numerous Drug Classes Studied for Use in Follicular and Other Lymphomas
A Guide to ASCO 2013: Key Targeted Trials
Full Version of the May 2013 Issue
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
